Assessment of clinical trials in gene therapy;Un bilan des essais cliniques en therapie genique

Bulletin du Cancer

Volumn 86, Issue 1, 1999, Pages 115-121

  Favrot, Marie C ^a   Coll, Jean Luc ^b   Puisieux, Isabelle ^a  

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT ALBERT BONNIOT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 7; TUMOR ANTIGEN; VIRUS VECTOR;

CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; GENE THERAPY; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NEUROBLASTOMA; REVIEW; TRANSGENE; TUMOR SUPPRESSOR GENE; VIRUS GENE;

ANTIGENS, NEOPLASM; CLINICAL TRIALS; CYTOKINES; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; GENETIC VECTORS; HLA ANTIGENS; HUMANS; NEOPLASMS; PRODRUGS; REGISTRIES;

EID: 0032913204     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Blaese RM, Culver KW, Miller AD, Carter CS, Fleischer T, Clcrici M, et al. T lymphocyte-directed gene therapy for ADA-SCID : initial trial results after 4 years. Science 1995 ; 270 : 475-80.
2. Site Wiley: http://www.wiley.co.uk/genetherapy/DATABASE/db/genesearch.cgi, 1998.
3. Merrouche Y, Négrier S, Bain C, Combaret V, Mercatello A, Coronel B, et al. Clinical application of retroviral gene transfer in oncology : results of a French study with tumor infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol 1995 ; 13 : 410-8.
4. Tursz T, Le Cesne A, Baldeyrou P, Gautier E, Opolon P, Schatz C, et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst 1996 ; 88 : 1857-63.
5. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson R, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995 ; 85 : 3048-57.
6. Perkus ME, Tartaglia J, Paoletti E. Poxvirus-based vaccine candidates for cancer, Aids, and other infectious diseases. J Leucoc Biol 1995 ; 58 : 1-13.
7. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, et al. Gene transfer into humans : immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocyres-modified by retroviral gene transduction. N Engl J Med 1990 ; 323 : 570-8.
8. Economou JS, Belldegrun AS, Glaspy J, Toloza EM, Figlin R, Hobbs J, et al. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. J Clin Invest 1996 ; 97 : 515-21.
9. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med 1996 ; 2 : 216-23.
10. Brenner MK, Rill DR, Moen RC, Krance PA, Mirro JJ, Anderson WF, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993 ; 341 : 85-6.
11. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigcnic cells. Blood 1994 ; 84 : 380-3.
12. Gahéry-Segard H, Molinier-Frenkel V, Le Boulaire C, Saulnier P, Opolon P, Lengagne R, et al. Phase I trial of recombinant adenovirus gene transfer in lung cancer. J Clin Invest 1997 ; 9 : 2218-26.
13. Registre Human gene marker/therapy clinical protocols. Hum Gene Ther 1998 ; 9 : 1803-47.
14. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plaurz GE, Gao X, et al. Direct gene transfer with DNA-liposome complexes in melanoma : expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993 ; 90 : 11307-11.
15. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996 ; 93 : 15388-93.
16. Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997 ; 15 : 341-9.
17. Rubln J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW, et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997 ; 4 : 419-25.
18. Hui KM, Ang PT, Huang L, Tay SK. Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DHA-liposome complexes. Gene Ther 1997 ; 4 : 783-90.
19. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappnne E, Ruggieri L, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graftversus-leukemia. Science 1997 ; 276 : 1719-24.
20. Tiberghien P. Modulation of alloreactivity using genetically modified T lymphocytes. Transfus Clin Biol 1997 ; 4 : 275-80.
21. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med 1997 ; 3 : 1354-61.
22. Long Z, Zi LP, Grooms T, Lockey C, Nader K, Mychkovsky I, et al. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther 1998 ; 9 : 1165-72.
23. Weber F, Bojar H, Priesack HB, Floeth F, Lenartz D, Kiwit J, et al. Gene therapy of glioblastoma - one year clinical experience with ten patients. J Mol Med 1997 ; 75 : B40 (126).
24. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy : results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998 ; 9 : 1083-92.
25. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996 ; 2 : 985-91.
26. Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, et al. Gene therapy for non-small cell lung cancer : a preliminary report of phase I trial of adenoviral p53 gene replacement. Semin Oncol 1998 ; 25 : 33-7.
27. Clayman G, El-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt A, et al. Adenuvirus-mediated p53 gene transfer in recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998 ; 16 : 2221-32.
28. Schuler M, Rochlitz C, Horowirz JA, Schlegel J, Perruchoud AP, Kommoss F, et al. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998 ; 9 : 2075-82.
29. Habib NA, Ding SF, El-Masry R, Mitry RR, Honda K, Michail NE, et al. Preliminary, report : the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev 1996 ; 20 : 103-7.
30. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, et al. BLC-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997 ; 349 : 1137-41.
31. Hanania EG, Giles RE, Kavanagh J, Ellrson D, Zu Z, Wang T, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hemato-poietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA 1996 ; 93 : 15346-51.
32. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Wahdat L, Balmaceda C, et al. Phase I trial of retroviral-mediated transfer of the human MDRI gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998 ; 16 : 165-72.
33. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Med 1998 ; 4 : 1068.
34. Heist C, Sampson-Johannes A, Williams A, McCormick F, von Hoff DD, Kirn DH. Onyx-015, an Elb gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 1997 ; 3 : 639-45.
35. Kren BT, Bandyopadhyay P, Steer CJ. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nature Med 1998 ; 4 : 285.
36. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997 ; 57 : 1537-46.
37. Sun Y, Jurgovsky K, Möller P, Alijagic S, Dorbic T, Georgieva J, et al. Vaccination with IL-12 gene-modified autologous melanoma cells : preclinical results and a first clinical phase I study. Gene Ther 1998 ; 5 : 481-90.
38. Abdel-Wahab Z, Weltz C, Hester D, Pickett N, Vervaert C, Barber JR, et al. A phase I clinical trial of immunotherapy with interferon-gamma genemodified autologous melanoma cells. Cancer 1997 ; 80 : 401-12.
39. Möller P, Sun Y, Dorbic T, Atijagic S, Makki A, Jurgovsky K, et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lyric activity in peripheral blood of patients with a good activity in peripheral blood of patients with a good clinical performance status : a clinical phase I study. Br J Cancer 1998 ; 77 : 1907-16.
40. Veelken H, Mackensen A, Lahn M, Köhler G, Becker D, Franke B, et al. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 1997 ; 70 : 269-77.
41. Jantscheff P, Bongartz G, Dietrich PY, Schatz C, Mehtali M, Courtney M, et al. Phase I study of cytokine-transfected xenogeneic cells (Vero-IL2) in patients with metastatic solid tumors. J Mol Med 1997 ; 75 : B(31).
42. Tan Y, Xu M, Wang W, Zhang F, Li D, Xu X, et al. IL-2 gene therapy of advanced lung cancer patients. Anticancer Res 1996 ; 16 : 1993-8.